Biometry uses biomarker data gathered from a breathalyzer and pairs it with predictive analytics and clinical oversight to prevent asthma attacks.
Sensor + Breathalyzer + App
Monitor Risk of Attack
Over 80% of patients who have severe asthma attacks think their disease is controlled.1 We identify patients at risk before they have symptoms or a decline in lung function.2
Monitor Rx Adherence and Efficacy
Alert and Adjust
What we measure
FeNO, a biomarker of airway inflammation that is reduced by anti-inflammatory medications. Elevated levels indicate risk of an asthma attack even if the patient doesn't have symptoms or a decline in lung function.2 The biomarker was added to the Global Initiative for Asthma Guidelines in 2017. Tailoring therapy based on FeNO can reduce the number and frequency of asthma attacks by 27-40%.2
Asthma is a chronic disease with acute episodes of temporary suffocation lasting minutes, hours or days. Despite this, over 80% of patients who have severe asthma attacks think their disease is well controlled.1 This results in non-adherence to therapy and failure to recognize the frequency and severity of symptoms.1
Biometry changes perceptions about asthma severity by delivering personalized insights showing patients when they are at risk for an attack even if they don't have symptoms.
Biomarker is elevated. Patient alerted of their risk and reminded to take their medication.
Patient uses inhaled steroid to reduce airway inflammation.
Biomarker levels are reduced within 1 day. Patients can visualize the anti-inflammatory effect of the drug and how it reduces risk of an attack.
Physicians and Payers
There are 26 million patients with asthma in the US. Approximately 13 million, or 50%, will have an asthma attack each year.3 17% of those attacks are severe enough to require an ER visit or hospitalization. The average cost of a hospitalization is over $12,000 in Missouri and $35,000 in California.4,5 The average cost of a less severe attack is $893 caused by unscheduled physician visits and increased drug costs.6
Biometry's solution identifies which patients are at risk inbetween physican visits. Our data is used to biologically identify patients who are non-adherent. It also monitors efficacy of therapy to guide medication selection and adjustment. Using FeNO to manage long-term control medications including dose titration, weaning, and monitoring of adherence reduces the number and frequency of asthma attacks by 27-40%.2,7
Monitoring asthma with Biometry
How it works
- Price D. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. npj Prim Care Respir Med. 2014. Severe asthma attacks requiring oral steroids, ER or Hospitalization
- Homan S, Vantuinen M, Gaddy PD and Yun S. The Burden of Asthma: Delineation of Acute Healthcare Utilization among Asthma Patients in Missouri, 2007-2009. Chronic Dis Int. 2016; 3(1): 1023.
- Centers for Disease Control http://www.cdc.gov/asthma/most_recent_data.htm Accessed September 8, 2018
- California Breathing Environmental Health Investigations Branch California Department of Public Health https://www.cdph.ca.gov/Programs/CCDPHP/DEODC/EHIB/CPE/CDPH%20Document%20Library/Asthma_in_California_Surveillance_Report_Slides.pdf Accessed September 4, 2018
- Global Initiative For Asthma. 2018 Global Initiative for Asthma Report: Global Strategy for Asthma Management and Prevention. https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/ Accessed September 4, 2018.
- Ivanova J. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol. 2012
- Wang Z, et Al. The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Comparative Effectiveness Review No. 197 (Prepared by the Mayo Clinic Evidence-based Practice Center under Contract No. 290-2015-00013-I). AHRQ Publication No.17(18)-EHC030-EF. Rockville, MD: Agency for Healthcare Research and Quality. December 2017.